1. Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P., 1995, Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial, Tumor Targeting 1:17–29.
2. Bagshawe, K., Springer, C. J., Searle, F., Antoniw, R, Sharma, S. K., Melton, R. G., and Sherwood, R. F., 1988, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58:700–703.
3. Blakey, D. C., Burke, R J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. R, Fitton, J. E., Mcdaid, J., Melton, R. G., Niculescu-duvaz, I. A., Pinder, P. E., Sharma, S. K., Wright, A. E, and Springer, C. J., 1996, ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts, Cancer Res. 56:3287–3892.
4. Blakey, D. C., Valcaccia, B. E., East, S., Wright, A. F., Boyle, E. H., Springer, C. J., Burke, R. B., Melton, R. G., and Bagshawe, K. D., 1993, Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug, Cell Biophys. 22:1–8.
5. Deierhoi, M. H., Kauffman, R. S., Hudson, S. L., Barber, W. H., Curtis, J. J., Julian, B. A., Gaston, R. S., Laskow, D. A., and Diethelm, A. G. (1993) Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center, Ann. Surg. 217:476–482.